Prognose
Analytikernes gennemsnitlige kursmål er 13,67 € (+395,29 %). Medianen er 13,67 € (+395,29 %).
| Køb |
4 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Armata Pharmaceuticals rises after FDA decision naming AP-SA02 a "Breakthrough Therapy"
Armata Pharmaceuticals’ stock rose sharply after the FDA granted the phage candidate AP-SA02 "Breakthrough Therapy" status for the adjuvant treatment of complicated Staphylococcus aureus bacteremia. The designation is based on phase 1b/2a data in which 100% of patients treated with AP-SA02 showed a sustained clinical response 28 days after end of therapy versus 75% in the placebo group. AP-SA02 also received Fast Track and Qualified Infectious Disease Product designations; the treatment was well tolerated without serious adverse events attributable to the product. » Mere på de.investing.com
Armata submits phase‑3 protocol for AP‑SA02 against resistant staphylococci to FDA
Armata has filed the complete phase‑3 protocol and responses to FDA feedback for the bacteriophage candidate AP‑SA02 to treat complicated S. aureus bacteremias. Four engineering runs have been completed in cGMP production in Los Angeles; production of clinical trial material and study start are planned for the second half of 2026. AP‑SA02 holds FDA designations Qualified Infectious Disease Product and Fast Track; the U.S. Department of Defense is funding development with an additional $2.5 million (total $28.7 million). Investors reacted positively, the share price rose markedly, and David House was promoted to CFO. » Mere på de.investing.com
Armata receives fast-track status from FDA for phage drug AP-SA02
The FDA has granted fast-track status to Armata’s intravenous multi-phage candidate AP-SA02 for the treatment of complicated S. aureus bacteremias, enabling more frequent interaction with the agency, rolling review of approval, and potentially accelerated approval. AP-SA02 showed positive Phase 1b/2a results, and Armata plans a Phase 3 superiority study in the second half of 2026. Analysts mostly rate the stock a buy with price targets of $15 to $20, although the company was recently unprofitable and reported a loss per share of $4.80. » Mere på de.investing.com
Armata Pharmaceuticals schedules annual general meeting for June 11
Armata Pharmaceuticals has scheduled its annual general meeting for June 11, 2026 at 8:30 a.m. Pacific Time at its headquarters in Los Angeles. Shareholders eligible to receive notice and vote are those recorded in the share register at the close of business on April 17, 2026; the deadline for shareholder proposals and director nominations is April 12, 2026 at 5:00 p.m. Pacific Time. The company also reported weak quarterly results: adjusted EPS of -$3.42 and revenue of $1.1 million, both well below expectations. » Mere på de.investing.com
Armata Pharmaceuticals: stock falls after delay of quarterly report despite FDA status for AP-SA02
Armata Pharmaceuticals delays publication of its Q4 and full-year 2025 report and expects to file the 10-K by no later than March 31, 2026, after which the stock dropped sharply. The FDA has granted the phage candidate AP-SA02 QIDP status, providing development incentives and the possibility of a five-year extension of market exclusivity; a Fast Track application has been submitted. The FDA considers the phase-2a data sufficient to start a phase-3 trial, planned to begin in the second half of 2026. In addition, the cGMP manufacturing facility in Los Angeles has been commissioned; market capitalization is around $310.91 million and an analysis suggests possible overvaluation. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Armata Pharmaceuticals en omsætning på 2,8 mio. € og et nettoresultat på 48,43 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 2,8 mio. | - |
| Bruttofortjeneste | 2,29 mio. | - |
| Nettoresultat | 48,43 mio. | 313,06 % |
| EBITDA | 55,61 mio. | 397,19 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 107,45 mio. € |
Antal aktier | 37,19 mio. |
Højeste/laveste i 52 uger | 13,65 € - 2,19 € |
| Udbytte | Nej |
Beta | 1,41 |
P/E (PE Ratio) | -0,93 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,00 |
P/S (PS Ratio) | 18,22 |
Virksomhedsprofil
Armata Pharmaceuticals, Inc., et klinisk fase-biotekselskab, fokuserer på udviklingen af målrettede bakteriofagbehandlinger mod antibiotikaresistente infektioner på verdensplan. Selskabet udvikler sine produkter ved hjælp af sin proprietære bakteriofagbaserede teknologi. Selskabets produktkandidater omfatter AP-SA02 til behandling af Staphylococcus aureus-bakteriæmi, AP-PA02 til Pseudomonas aeruginosa og AP-PA03 til behandling af lungebetændelse. Selskabet har en partneraftale med Merck & Co. om udvikling af syntetiske bakteriofagkandidater, der skal målrette uoplyste infektionssygdomsagenser. Selskabets hovedkontor ligger i Marina del Rey, Californien.
| Navn | Armata Pharmaceuticals |
| CEO | Deborah L. Birx |
| Hjemsted | Los Angeles,
ca USA |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 20.05.1994 |
| Medarbejdere | 61 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
AMEX | ARMP |
Frankfurt | TG1N.F |
München | TG1N.MU |
Düsseldorf | TG1N.DU |